Saúde Pública/Medicina Humanitária

Nem todas as ondas de Covid são parecidas. Uma análise do aumento da variante Delta.

9 Nov, 2021 | 12:17h

Not all Covid waves look the same. Here’s a snapshot of the Delta surge – STAT

Comentário no Twitter

If you know someone on the fence about vaccination, show them this https://t.co/ndPLhpLlh4 pic.twitter.com/L6RLwHyGCi

— David Juurlink (@DavidJuurlink) November 8, 2021

Ações para transformar os métodos da USPSTF visando a mitigar o racismo sistêmico nos serviços médicos preventivos.

9 Nov, 2021 | 12:16h

Actions to Transform US Preventive Services Task Force Methods to Mitigate Systemic Racism in Clinical Preventive Services – JAMA

Ver também: Addressing Racism in Preventive Services: Methods Report to Support the US Preventive Services Task Force – JAMA

Comentário: USPSTF Proposes Strategies to Mitigate Racism in Preventive Care – HealthDay

Revisão sistemática | Tratamento de pacientes de alta necessidade e alto custo.

9 Nov, 2021 | 12:12h

Management of High-Need, High-Cost Patients: A “Best Fit” Framework Synthesis, Realist Review, and Systematic Review – Agency for Healthcare Research and Quality

Ver também:

Evidence Summary

Final Report

Conteúdos relacionados:

Designing a High-Performing Health Care System for Patients with Complex Needs: Ten Recommendations for Policymakers – The Commonwealth fund

Effective Care for High-Need Patients: Opportunities for Improving Outcomes, Value, and Health – National Academy of Medicine

Systematic review of high-cost patients’ characteristics and healthcare utilization – BMJ Open

Effectiveness of interventions for managing multiple high-burden chronic diseases in older adults: a systematic review and meta-analysis – Canadian Medical Association Journal

Multimorbidity: a priority for global health research – The Academy of Medical Sciences

The global burden of multiple chronic conditions: A narrative review – Preventive Medicine Reports

Redesigning Care for High-Cost, High-Risk Patients – Harvard Business Review

Multimorbidity: clinical assessment and management – NICE Guideline

Multimorbidity in Older Adults with Cardiovascular Disease – American College of Cardiology, Latest in Cardiology

Richard Smith: The challenge of high need, high cost patients – The BMJ Blogs

Better Care for People with Complex Needs – Institute for Healthcare Improvement

Comunicado de imprensa – ainda não publicado] Estudo randomizado | Novo antiviral oral da Pfizer, candidato a tratamento da Covid-19, reduziu o risco de internação ou morte em 89% em análise interina da fase 2/3 do estudo EPIC-HR.

8 Nov, 2021 | 12:47h

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Comentários:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

Comentário no Twitter (fio – clique para saber mais)

Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt

— David Boulware, MD MPH (@boulware_dr) November 5, 2021